Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma
About this trial
This is an interventional treatment trial for Diffuse Large B Cell Lymphoma focused on measuring Curative effect evaluation, Adverse reactions, Clinical characteristics, PR, PFS, OS
Eligibility Criteria
Inclusion Criteria:
- Above 70 years old,Pathology proved to be diffuse large B cell lymphoma,Estimated survival time > 3 months,None of chemotherapy contraindication;At least one measurable lesion according to RECIST;None of other serious diseases;Patients could be followed up;None of other relative treatments including the traditional Chinese medicine, immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic treatments.
volunteers who signed informed consent.
Exclusion Criteria:
- Currently undergoing chemotherapy, radiotherapy and targeted therapy (received chemotherapy within 3 weeks, received radiotherapy within 2 weeks, or has not recovered from any previous treatment of acute toxicity);Patients with uncontrolled medical problems (including active infection, uncontrolled diabetes, severe heart, liver, kidney dysfunction and interstitial pneumonia, etc.); Pregnant or lactating women;Serious medical illness likely to interfere with participation;Chemotherapy contraindication such as cachexia; patients with other malignancies previously;Serious infection;The evidence of peripheral nervous disorder or dysphrenia; patients estimated to be unsuitable by investigator.
Sites / Locations
- Oncology Department of The First Affiliated Hospital of Zhengzhou UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
(R)-CHOP regimen
(R)-CVP regimen
(R)-CHOP regimen((rituximab),cyclophosphamide,epirubicin,vincristine and prednisone),(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
(R)-CVP regimen((rituximab),cyclophosphamide,vincristine and prednisone) The dose of the chemical was reduced by 20%,(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt), oral cyclophosphamide .